Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with SCIg (very low certainty).
1 finding from 1 review
RR 0.5 [0.18, 1.4]
9 participants
Very low
Proportion of participants with an improvement in disability scale used in the original study · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants with an improvement in disability scale… compared with placebo (low certainty).
1 finding from 1 review
RR 3 [0.89, 10.12]
18 participants
Low
Proportion of participants with an improvement of muscle strength · people with multifocal motor neuropathy
IVIg may leads to higher proportion of participants with an improvement of muscle strength compared with placebo (low certainty).
1 finding from 1 review
RR 11 [2.86, 42.25]
27 participants
Low
Proportion of participants with an improvement in disability at 12 months or later · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants in which at least 1 conduction block… compared with placebo (low certainty).
1 finding from 1 review
RR 7 [0.95, 51.7]
28 participants
Low
Maintenance · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to higher proportion of IVIg‐treated participants with an increase in… compared with placebo (moderate certainty).
1 finding from 1 review
RR 2.43 [1.13, 5.24]
42 participants
Moderate
Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to lower proportion of IVIg‐treated participants with a decrease in muscle… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.2 [0.07, 0.54]
42 participants
Moderate
Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with placebo (very low certainty).
1 finding from 1 review
RR 10.33 [2.15, 49.77]
21 participants
Very low
Seizure freedom · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfactory seizure control 50% or greater reduction in seizure frequency for drug‐resistant epilepsy · patients with drug‐resistant epilepsy
IVIg showed no clear difference in satisfactory seizure control 50% or greater reduction in seizure… compared with placebo (low certainty).
1 finding from 1 review
All harmful effects · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global assessment · patients with drug‐resistant epilepsy
IVIg may leads to higher global assessment compared with placebo (low certainty).
1 finding from 1 review
Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · patients with Guillain‐Barré syndrome
1 finding from 1 review
Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).
1 finding from 1 review
Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).
1 finding from 1 review
Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).
1 finding from 1 review
Patients in whom treatment was discontinued · patients with Guillain‐Barré syndrome
IVIg leads to lower participants in whom treatment was discontinued compared with PE (high certainty).
1 finding from 1 review
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review